down arrow

Cogent Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US19240Q2012
USD
39.31
0.33 (0.85%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

37.9439.58

52 Week

3.7241.27
Valuation
Technical
Day's Volume

CASH

2.47 M

Shareholding (Mar 2025)

FII

7.60%

Held by 91 FIIs

DII

43.37%

Held by 47 DIIs

Promoter

17.86%

How big is Cogent Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Cogent Biosciences, Inc. has a market capitalization of 867.59 million and reported net sales of 0.00 million with a net profit of -269.50 million over the last four quarters. Shareholder's funds were 256.29 million, and total assets amounted to 327.90 million as of Dec 24.

As of Jun 18, Cogent Biosciences, Inc. has a market capitalization of 867.59 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -269.50 million during the same period.<BR><BR>As of Dec 24, the shareholder's funds were 256.29 million, and the total assets amounted to 327.90 million.

Read More

What does Cogent Biosciences, Inc. do?

22-Jun-2025

Cogent Biosciences, Inc. is a biopharmaceutical company focused on developing precision therapies for genetically defined diseases and curative cell therapies for solid tumors. It operates as a micro-cap company with a market cap of approximately $867.59 million and reported a net profit loss of $72 million in March 2025.

Overview:<BR>Cogent Biosciences, Inc. is a biopharmaceutical company focused on developing precision therapies for genetically defined diseases and curative cell therapies for solid tumors, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: Not available<BR>Most recent Net Profit: -72 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 867.59 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.11<BR>Return on Equity: -123.06%<BR>Price to Book: 3.96<BR><BR>Contact Details:<BR>Address: 200 CAMBRIDGE PARK DRIVE, SUITE 3100, CAMBRIDGE MA: 02140<BR>Tel: ['1 617 9455576', '1 212 3621200']<BR>Website: https://www.unumrx.com/

Read More

Who are in the management team of Cogent Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Cogent Biosciences, Inc. includes Andrew Robbins (President and CEO), Chris Cain, Peter Harwin, Karen Ferrante, Arlene Morris, and Matthew Ros, all of whom guide the company's strategic direction and operations.

As of March 2022, the management team of Cogent Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. Andrew Robbins, who serves as the President, Chief Executive Officer, Principal Executive Officer, and Director.<BR>- Dr. Chris Cain, who is a Director.<BR>- Mr. Peter Harwin, who is also a Director.<BR>- Dr. Karen Ferrante, who serves as an Independent Director.<BR>- Ms. Arlene Morris, who is another Independent Director.<BR>- Mr. Matthew Ros, who is also an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Cogent Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of May 12, 2021, Cogent Biosciences, Inc. is considered overvalued due to negative financial ratios and poor stock performance, indicating significant operational challenges compared to its peers.

As of 12 May 2021, the valuation grade for Cogent Biosciences, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its negative financial ratios, including a Price to Book Value of 3.54, an EV to EBIT of -1.84, and an ROE of -123.06%. These figures suggest that the company is not generating returns on equity and is facing substantial operational challenges.<BR><BR>In comparison to its peers, Cogent's valuation metrics are considerably worse. For instance, Protagonist Therapeutics, Inc. has a P/E ratio of 60.90, while Deciphera Pharmaceuticals, Inc. shows a P/E of -11.62, both indicating a stark contrast to Cogent's situation. The company's recent stock performance has also been lackluster, with a one-year return of -17.41% compared to the S&P 500's 10.26%, further reinforcing the notion that Cogent is overvalued in its current state.

Read More

Is Cogent Biosciences, Inc. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, Cogent Biosciences, Inc. shows a mildly bullish trend with strong indicators like MACD and Bollinger Bands, despite mixed signals from the RSI and Dow Theory, and has returned 60.38% year-to-date, outperforming the S&P 500.

As of 19 September 2025, the technical trend for Cogent Biosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the RSI shows a bearish signal. The daily moving averages are bullish, and the KST is bullish on both weekly and monthly time frames. However, Dow Theory presents a mildly bearish view on the weekly chart, contrasting with a mildly bullish monthly perspective. <BR><BR>In terms of performance, the stock has returned 60.38% year-to-date, significantly outperforming the S&P 500's 13.31% during the same period, although it has underperformed over the longer 3-year and 5-year horizons. Overall, the current technical stance is mildly bullish, driven by strong indicators like MACD and Bollinger Bands, despite some mixed signals from the RSI and Dow Theory.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,771 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.24

stock-summary
Return on Equity

-183.23%

stock-summary
Price to Book

11.43

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-74 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
200.54%
0%
200.54%
6 Months
578.93%
0%
578.93%
1 Year
327.75%
0%
327.75%
2 Years
393.22%
0%
393.22%
3 Years
204.49%
0%
204.49%
4 Years
376.48%
0%
376.48%
5 Years
207.35%
0%
207.35%

Cogent Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Cogent Biosciences, Inc. technically bullish or bearish?

As of 19 September 2025, the technical trend for Cogent Biosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the RSI shows a bearish signal. The daily moving averages are bullish, and the KST is bullish on both weekly and monthly time frames. However, Dow Theory presents a mildly bearish view on the weekly chart, contrasting with a mildly bullish monthly perspective. In terms of performance, the stock has returned 60.38% year-to-date, significantly outperforming the S&P 500's 13.31% during the same period, although it has underperformed over the longer 3-year and 5-year horizons. Overall, the current technical stance is mildly bullish, driven by strong indicators like MACD and Bollinger Bands, despite some mixed signals from the RSI and Dow Theory....

Read More

Is Cogent Biosciences, Inc. technically bullish or bearish?

As of 19 September 2025, the technical trend for Cogent Biosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the weekly RSI is bearish, indicating mixed signals. The Bollinger Bands and moving averages are both showing mildly bullish trends on the daily and weekly time frames. However, the On-Balance Volume is mildly bearish on both weekly and monthly charts. In terms of performance, the stock has underperformed the S&P 500 over the past week and year, with a return of -5.45% compared to the S&P's 1.22% for the week and 9.82% compared to the S&P's 16.64% for the year. Overall, the current technical stance is mildly bullish, but with caution due to the bearish RSI and OBV indicators....

Read More

Is Cogent Biosciences, Inc. technically bullish or bearish?

As of 26 August 2025, the technical trend for Cogent Biosciences, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. Additionally, Bollinger Bands are bullish on both time frames, and the daily moving averages also indicate a bullish stance. However, the weekly RSI is bearish, which suggests some short-term weakness. The KST is bullish on both weekly and monthly charts, while the Dow Theory shows a mildly bullish monthly trend but no trend on the weekly. The OBV indicates mild bearishness on both weekly and monthly time frames. In terms of performance, Cogent has a year-to-date return of 63.08%, significantly outperforming the S&P 500's 12.22%, although it has underperformed over the 3-year and 5-year periods compared to the benchmark. Overall, the current technical stance is bullish, with strength indicated by the MACD a...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-261.23%
EBIT to Interest (avg)
-161.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.11
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.54
EV to EBIT
-1.84
EV to EBITDA
-1.87
EV to Capital Employed
-21.16
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-123.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 44 Schemes (31.17%)

Foreign Institutions

Held by 91 Foreign Institutions (7.6%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -24.58% vs -33.79% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-74.40",
          "val2": "-63.30",
          "chgp": "-17.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-73.50",
          "val2": "-59.00",
          "chgp": "-24.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -33.00% vs -37.23% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-271.50",
          "val2": "-204.50",
          "chgp": "-32.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-255.90",
          "val2": "-192.40",
          "chgp": "-33.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-74.40
-63.30
-17.54%
Interest
0.30
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-73.50
-59.00
-24.58%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -24.58% vs -33.79% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-271.50
-204.50
-32.76%
Interest
0.00
0.00
Exceptional Items
0.00
1.70
-100.00%
Consolidate Net Profit
-255.90
-192.40
-33.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -33.00% vs -37.23% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cogent Biosciences, Inc. stock-summary
stock-summary
Cogent Biosciences, Inc.
Pharmaceuticals & Biotechnology
Cogent Biosciences, Inc., formerly Unum Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing precision therapies for genetically defined diseases. The Company also engaged in developing curative cell therapies for solid tumors. Its proprietary technology includes bolt-on chimeric receptor (BOXR), designed to overcome resistance of the solid tumor microenvironment (TME) to T cell attack. The Company also developed product candidates using its proprietary technology, antibody-coupled T cell receptor (ACTR), an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability. Its preclinical program offers, BOXR1030, for the treatment of solid tumor cancers and PLX9486, is a tyrosine kinase inhibitor that is designed to inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 to treat systemic mastocytosis and gastrointestinal stromal tumors (GIST) patients.
Company Coordinates stock-summary
Company Details
200 CAMBRIDGE PARK DRIVE, SUITE 3100 , CAMBRIDGE MA : 02140
stock-summary
Tel: 1 617 94555761 212 3621200
stock-summary
https://www.unumrx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."